These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27926593)

  • 1. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
    Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
    Tapper EB; Hughes MS; Buti M; Dufour JF; Flamm S; Firdoos S; Curry MP; Afdhal NH
    Transplantation; 2017 May; 101(5):987-995. PubMed ID: 27495755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
    Zhang S; Bastian ND; Griffin PM
    BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
    J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
    Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Njei B; McCarty TR; Fortune BE; Lim JK
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
    Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
    Hagan LM; Sulkowski MS; Schinazi RF
    Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.